BRPI0924827A2 - identificação, otimização e uso de epítopos hla-a24 crípticos para imunoterapia - Google Patents

identificação, otimização e uso de epítopos hla-a24 crípticos para imunoterapia

Info

Publication number
BRPI0924827A2
BRPI0924827A2 BRPI0924827A BRPI0924827A BRPI0924827A2 BR PI0924827 A2 BRPI0924827 A2 BR PI0924827A2 BR PI0924827 A BRPI0924827 A BR PI0924827A BR PI0924827 A BRPI0924827 A BR PI0924827A BR PI0924827 A2 BRPI0924827 A2 BR PI0924827A2
Authority
BR
Brazil
Prior art keywords
hla
immunotherapy
optimization
identification
cryptic epitopes
Prior art date
Application number
BRPI0924827A
Other languages
English (en)
Inventor
Menez-Jamet Jeanne
Kostantinos, (Kostas) Kosmatopoulos
Original Assignee
Vaxon Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaxon Biotech filed Critical Vaxon Biotech
Publication of BRPI0924827A2 publication Critical patent/BRPI0924827A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
BRPI0924827A 2009-04-02 2009-04-02 identificação, otimização e uso de epítopos hla-a24 crípticos para imunoterapia BRPI0924827A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2009/005753 WO2010112962A1 (en) 2009-04-02 2009-04-02 Identification, optimization and use of cryptic hla-a24 epitopes for immunotherapy

Publications (1)

Publication Number Publication Date
BRPI0924827A2 true BRPI0924827A2 (pt) 2019-01-08

Family

ID=41381983

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0924827A BRPI0924827A2 (pt) 2009-04-02 2009-04-02 identificação, otimização e uso de epítopos hla-a24 crípticos para imunoterapia

Country Status (13)

Country Link
US (1) US8900600B2 (pt)
EP (1) EP2413956B1 (pt)
JP (1) JP5756792B2 (pt)
CN (1) CN102387813B (pt)
BR (1) BRPI0924827A2 (pt)
CA (1) CA2756238A1 (pt)
DK (1) DK2413956T3 (pt)
ES (1) ES2608715T3 (pt)
HR (1) HRP20161710T1 (pt)
HU (1) HUE030195T2 (pt)
PL (1) PL2413956T3 (pt)
PT (1) PT2413956T (pt)
WO (1) WO2010112962A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6702855B2 (ja) * 2013-04-07 2020-06-03 ザ・ブロード・インスティテュート・インコーポレイテッド 個別化された新生物ワクチンの組成物及び方法
EP3060232B1 (en) 2013-10-23 2018-07-04 The United States of America, as represented by The Secretary, Department of Health and Human Services Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
EP2886127A1 (en) * 2013-12-18 2015-06-24 Vaxon Biotech Method for emulsifying a triepitope peptide with montanide and kits for performing the same
CN120695169A (zh) 2013-12-20 2025-09-26 博德研究所 使用新抗原疫苗的联合疗法
EP2977059A1 (en) * 2014-07-22 2016-01-27 Vaxon Biotech Immunogenic polypeptide composed of HLA-B7 restricted tumor antigen-derived optimized cryptic peptides, and uses thereof
WO2016100977A1 (en) 2014-12-19 2016-06-23 The Broad Institute Inc. Methods for profiling the t-cel- receptor repertoire
WO2016100975A1 (en) 2014-12-19 2016-06-23 Massachsetts Institute Ot Technology Molecular biomarkers for cancer immunotherapy
EP3297660A2 (en) 2015-05-20 2018-03-28 The Broad Institute Inc. Shared neoantigens
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
EP3935172A4 (en) * 2019-03-04 2022-12-28 University Health Network T-CELL RECEPTORS AND METHODS OF USE THEREOF
SG11202109591QA (en) 2019-03-04 2021-10-28 Univ Health Network T cell receptors and methods of use thereof
AU2020231693A1 (en) 2019-03-04 2021-09-30 University Health Network T cell receptors and methods of use thereof
KR20210144782A (ko) * 2019-03-25 2021-11-30 유니버시티 헬스 네트워크 T 세포 수용체 및 이의 사용 방법
CN111363026B (zh) * 2020-03-31 2022-03-25 浙江省中医院、浙江中医药大学附属第一医院（浙江省东方医院） 一种增强抗原多肽亲和力和稳定性的方法
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
CN116710115A (zh) 2020-11-20 2023-09-05 思维疗法股份有限公司 用于优化的肽疫苗的组合物和方法
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
WO2024138753A1 (zh) * 2022-12-30 2024-07-04 深圳吉诺因生物科技有限公司 一种hla-a*24:02限制性抗原点替换方法、获得的多肽及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6337200B1 (en) 1998-03-31 2002-01-08 Geron Corporation Human telomerase catalytic subunit variants
EP1455816A4 (en) * 2000-10-19 2007-03-28 Epimmune Inc HLA CLASS I AND II BINDING PEPTIDES AND THEIR USE
JP4624377B2 (ja) * 2001-12-10 2011-02-02 株式会社グリーンペプタイド 腫瘍抗原
EP1462456A4 (en) * 2001-12-10 2005-09-21 Greenpeptide Co Ltd TUMOR ANTIGENS
US20060018915A1 (en) * 2002-04-05 2006-01-26 Glenn Ishioka Heteroclitic analogs and related methods
US7619058B2 (en) 2004-01-20 2009-11-17 Aichi Prefecture Epitope/peptide recognized by HLA-A2402-restricted Ep-CAM-specific CTL and use of the same
US20090202499A1 (en) 2006-01-19 2009-08-13 The Regents Of The University Of California Human Telomerase Reverse Transcriptase Peptides
WO2008010010A1 (en) * 2006-07-12 2008-01-24 Vaxon Biotech Identification, optimization and use of cryptic hla-b7 epitopes for immunotherapy

Also Published As

Publication number Publication date
CA2756238A1 (en) 2010-10-07
HRP20161710T1 (hr) 2017-02-24
JP5756792B2 (ja) 2015-07-29
EP2413956A1 (en) 2012-02-08
DK2413956T3 (en) 2017-01-09
US20120082692A1 (en) 2012-04-05
CN102387813B (zh) 2018-07-31
EP2413956B1 (en) 2016-09-14
PL2413956T3 (pl) 2017-06-30
US8900600B2 (en) 2014-12-02
WO2010112962A1 (en) 2010-10-07
HUE030195T2 (en) 2017-04-28
ES2608715T3 (es) 2017-04-12
JP2012522500A (ja) 2012-09-27
CN102387813A (zh) 2012-03-21
PT2413956T (pt) 2016-12-30

Similar Documents

Publication Publication Date Title
BRPI0924827A2 (pt) identificação, otimização e uso de epítopos hla-a24 crípticos para imunoterapia
BR112012004807A2 (pt) vacina para pcsk9
BRPI1010775A2 (pt) composição, método para preparar uma composição, e, uso de uma composição.
BR112013004025A2 (pt) amarra para uso hortícola
BRPI0924556A2 (pt) "identificação, otimização e uso de epítopos hla-b*0702 compartilhados para imunoterapia"
BRPI1014572A2 (pt) imidazoprazinas para uso como inibidores de cinase
BR112012019936A2 (pt) uso de um composto, método de preparação de um composto, método e composto
BR112012001797A2 (pt) composto bicíclico e uso do mesmo para propósitos médicos
BR112013006092A2 (pt) laminado, matéria-prima do laminado, método para preparação de um laminado e uso do laminado
PL2565204T3 (pl) Nowe immunogenne epitopy do immunoterapii
BRPI1010937A2 (pt) composto, uso de um composto, e, método para tratar câncer
BR112013024395A2 (pt) método e composições para imunoterapia celular
BR112013030994A2 (pt) uso de marcador raman para autenticação de documentos de segurança.
UY33094A (es) Procedimiento para la preparacion de dronedarona
CR20140212A (es) Anticuerpos anti-htra1 y métodos de uso
PT2855394T (pt) Ligantes de cimento, ativadores e métodos para preparar betão
BRPI1010859A2 (pt) aptâmero para quimase, e uso do mesmo
BRPI0924981A2 (pt) vacinas para câncer cervical.
BR112014005406A2 (pt) composição de vacina e respectivo uso
BR112014009178A2 (pt) métodos, uso, receptor e invenção
BR112014008088A2 (pt) método para detectar anticorpos, uso de um método, e, kit
BR112013028894A2 (pt) composto de tiazol, métodos para preparação e uso do mesmo
BR112013015085A2 (pt) composição farmacêutica, método para preparar uma composição, e, uso de composição
BRPI1012047A2 (pt) compostos dímeros contendo oxazolidinona, composições e métodos para fazer e uso
BRPI1013597A2 (pt) seringa para uso único

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]